Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

Multiple Sclerosis

Volumn 22, Issue 9, 2016, Pages 1215-1223

  Willis, M D ^a,b   Harding, K E ^a,b   Pickersgill, T P ^b   Wardle, M ^b   Pearson, O R ^c   Scolding, N J ^d   Smee, J ^b   Robertson, N P ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c MORRISTON HOSPITAL   (United Kingdom)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

alemtuzumab; autoimmunity; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; ANTINUCLEAR ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CENTROMERE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; PARAPROTEIN; PARIETAL CELL ANTIBODY; RHEUMATOID FACTOR; SMOOTH MUSCLE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; AUTOANTIBODY; AZATHIOPRINE; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; NATALIZUMAB;

ADULT; ALOPECIA; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE ALVEOLITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; BASAL CELL CARCINOMA; CELLULITIS; CHOLANGITIS; CONJUNCTIVITIS; CRYPTOSPORIDIOSIS; DISABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GENITAL HERPES; HEMOLYTIC ANEMIA; HERPES ZOSTER; HUMAN; HYPERTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFLUENZA; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MASTITIS; MENINGIOMA; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MUMPS; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCYTOPENIA; PITYRIASIS; PRECANCER; PREGNANCY RATE; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; RECURRENCE RISK; RESPIRATORY TRACT INFECTION; RETREATMENT; SIDE EFFECT; SINUSITIS; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; TONSILLITIS; URINARY TRACT INFECTION; UTERINE CERVIX DYSPLASIA; VITILIGO; AUTOIMMUNITY; CLINICAL TRIAL; CONVALESCENCE; DRUG EFFECTS; IMMUNOLOGY; MULTICENTER STUDY; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT; CLINICAL OUTCOME; COHORT ANALYSIS; LONG TERM CARE; LUNG ALVEOLITIS; MALIGNANT NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY;

ADULT; ALEMTUZUMAB; AUTOIMMUNITY; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT;

EID: 84979517136     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515614092     Document Type: Article

References (32)

1. Hale G,. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137-143.
2. Rao SP, Sancho J, Campos-Rivera J, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012; 7 (6): e39416.
3. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009; 128 (2): 260-270.
4. Klotz L, Meuth SG, Wiendl H,. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 2012; 142: 25-30.
5. Fox EJ,. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother 2010; 10 (12): 1789-1797.
6. Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 2013; 80 (1): 55-61.
7. Kousin-Ezewu O, Azzopardi L, Parker RA, et al. Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology 2014; 82 (24): 2158-2164.
8. Robertson N, Scolding N,. Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab. Neurology 2014; 82 (24): 2150-2151.
9. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994; 344 (8918): 298-301.
10. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46 (3): 296-304.
11. Coles A, Deans J, Compston A,. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004; 106 (3): 270-274.
12. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253 (1): 98-108.
13. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008; 255 (2): 231-238.
14. Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 2012; 19 (2): 307-311.
15. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab versus interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359 (17): 1786-1801.
16. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380 (9856): 1819-1828.
17. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380 (9856): 1829-1839.
18. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78 (14): 1069-1078.
19. Coles AJ,. Alemtuzumab treatment of multiple sclerosis. Semin Neurol 2013; 33 (1): 66-73.
20. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119 (Pt 1): 225-237.
21. Weinshenker BG, Bass B, Rice GP, et al. the Natural history of multiple sclerosis: a geographically based study. Brain 1989; 112 (1): 133-146.
22. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343 (2): 1430-1438.
23. Poser S, Poser W, Schlaf G, et al. Prognostic indicators in multiple sclerosis. Acta Neurol Scand 1986; 74 (5): 387-392.
24. Visscher BR, Liu KS, Clark VA, et al. Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol Scand 1984; 70 (5): 321-328.
25. Cossburn M, Ingram G, Hirst C, et al. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler 2012; 18 (1): 45-54.
26. Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015; 86 (2): 208-215.
27. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology 2012; 78 (14): 1069-1078.
28. Cossburn M, Pace A, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011; 77 (6): 573-579.
29. Pace A, Zajicek JP,. Melanoma following treatment with alemtuzumab for multiple sclerosis. Eur J Neurol 2009; 16 (4): e70-71.
30. Coles A,. Alemtuzumab treatment of multiple sclerosis. Semin Neurol 2013; 33: 66-73.
31. Denslow SA, Rositch AF, Firnhaber C, et al. Incidence and progression of cervical lesions in women with HIV: a systematic global review. Int J STD AIDS 2014; 25 (3): 163-177.
32. Medd P, Littlewood S, Danby R, et al. Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation. Bone Marrow Transplant 2011; 46 (7): 993-999.